Abstract

The mechanism underlying unwanted structural variations induced by CRISPR-Cas9 remains poorly understood, and no effective strategy is available to inhibit the generation of these byproducts. Here we find that the generation of a high level of translocations is dependent on repeated cleavage at the Cas9-targeting sites. Therefore, we employ a strategy in which Cas9 is fused with optimized TREX2 to generate Cas9TX, a Cas9 exo-endonuclease, which prevents perfect DNA repair and thereby avoids repeated cleavage. In comparison with CRISPR-Cas9, CRISPR-Cas9TX greatly suppressed translocation levels and enhanced the editing efficiency of single-site editing. The number of large deletions associated with Cas9TX was also reduced to very low level. The application of CRISPR-Cas9TX for multiplex gene editing in chimeric antigen receptor T cells nearly eliminated deleterious chromosomal translocations. We report the mechanism underlying translocations induced by Cas9, and propose a general strategy for reducing chromosomal abnormalities induced by CRISPR-RNA-guided endonucleases.

Chromosomal structural variations induced by CRISPR/Cas hinder its application in clinics. Here, the authors fuse Cas9 with optimized TREX2 to generate Cas9TX, which can prevent perfect repair and inhibit repeated cleavage.

Details

Title
Cas9 exo-endonuclease eliminates chromosomal translocations during genome editing
Author
Yin Jianhang 1 ; Lu Rusen 1 ; Changchang, Xin 1 ; Wang, Yuhong 1 ; Ling Xinyu 2 ; Li, Dong 1 ; Zhang, Weiwei 1 ; Liu Mengzhu 1 ; Xie Wutao 1 ; Kong Lingyun 1 ; Si Wen 1 ; Wei, Ping 1 ; Xiao Bingbing 3 ; Hsiang-Ying, Lee 1   VIAFID ORCID Logo  ; Liu, Tao 2   VIAFID ORCID Logo  ; Hu Jiazhi 1   VIAFID ORCID Logo 

 Peking University, The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Center for Life Sciences, Genome Editing Research Center, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319) 
 Peking University, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319) 
 Peking University First Hospital, Department of Obstetrics and Gynecology, Beijing, China (GRID:grid.411472.5) (ISNI:0000 0004 1764 1621) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2637578585
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.